David Kabakoff
InvestorExecutive Partner, Private Equity at Sofinnova Ventures
About
David Kabakoff is a medicinal chemist with more than 30 years of experience leading technology and product development in the pharmaceutical, biopharmaceutical, and drug delivery fields. Before joining Sofinnova in 2007, he co-founded the cancer drug developer Salmedix, serving as Chairman and CEO until its acquisition by Cephalon, and previously held executive roles at Dura, Spiros Development, Corvas International, and Hybritech. He holds a PhD from Yale University and a BA from Case Western Reserve University.
Invests in
Biotech
Deals · 2
NextCure, Inc.Board seat
via Sofinnova Ventures · filed Dec 2025 · $21.5M raise
RarecyteBoard seat
via Sofinnova Ventures · filed Jul 2023 · $35.7M raise
Attribution from SEC filings, press coverage, and firm rosters.
